Innovative drug export trends continue to improve, presenting opportunities to strategically build positions in Hang Seng Biotechnology ETF (520930) and Tech Innovation Pharmaceutical ETF (589720) on dips.

On March 24, the pharmaceutical sector also performed well, with the Sci-Tech Innovation Drug ETF (589720) soaring 4.68% and the Hang Seng Biotech ETF (520930) rising 4.18%.

Source: Wind

The 2026 government work report explicitly lists biomedicine as a “new pillar industry.” When introducing this year’s government work tasks, the report emphasizes greater efforts to safeguard and improve people’s livelihoods, with strengthening basic medical and health services as one of the overall requirements. Additionally, in the task of cultivating and expanding new drivers of growth, biomedicine is also listed as one of the emerging and future industries to be nurtured and expanded.

The clinical research and development of innovative drugs is progressing steadily. Recently, domestic innovative drugs have disclosed excellent clinical data at multiple academic conferences, with a focus on key events such as the Q2 ASCO conference. Since the first quarter of 2026, the trend of domestic innovative drugs going abroad has continued, supported by multiple project cooperation agreements based on core technology platforms, fully demonstrating that China’s innovative drug R&D capabilities are increasingly recognized by multinational pharmaceutical companies, with further advantages in efficiency and cost.

In 2025, the CXO industry performance showed divergence. Most CDMO companies demonstrated strong profit growth, while some clinical CRO companies faced demand fluctuations and cost pressures, resulting in performance pressure. From the order perspective, the CXO industry’s order performance in 2025 shows positive signals, indicating that after the global biopharmaceutical investment and financing recovery, demand in the CXO sector is rebounding.

Furthermore, under the wave of AI technology, the pharmaceutical industry is expected to release new growth logic, with rapid development in brain-computer interfaces, AI medical care, and other areas. The pharmaceutical sector has relatively clean chips, with potential selling pressure easing, providing a higher safety margin and investment window for possible bottoming out and rebound. Upcoming industry catalysts such as the ASCO conference are approaching, and interested investors may consider gradually deploying the Hang Seng Biotech ETF (520930) and the Sci-Tech Innovation Drug ETF (589720) on dips.

Risk Reminder:

Investors should fully understand the differences between regular fixed investments and lump-sum savings methods. Regular fixed investment is a simple and effective way to guide investors toward long-term investment and average cost. However, regular fixed investment cannot eliminate the inherent risks of fund investment, cannot guarantee returns, and is not an equivalent financial product to savings.

Whether it is stock ETFs/LOFs or other securities, they belong to high expected risk and return investment products, with higher expected returns and risks than hybrid funds, bond funds, and money market funds.

Funds investing in STAR Market and ChiNext stocks face specific risks due to differences in investment targets, market systems, and trading rules, which investors should be aware of.

The short-term rise and fall of sectors/funds shown here are only auxiliary materials for analytical viewpoints and are for reference only. They do not guarantee fund performance.

The short-term performance of individual stocks mentioned in the article is for reference only, not a stock recommendation, nor a prediction or guarantee of fund performance.

The above opinions are for reference only and do not constitute investment advice or promises. If you wish to purchase related fund products, please pay attention to investor suitability management regulations, conduct risk assessments in advance, and choose fund products matching your risk tolerance. Funds carry risks; please invest cautiously.

Daily Economic News

(Edited by: Zhang Xiaobo)

【Disclaimer】This article only reflects the author’s personal views and is not related to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions in this article and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers should use it for reference only and bear all responsibilities themselves. Email: news_center@staff.hexun.com